Literature DB >> 28752221

DNA methylation profiles in cancer diagnosis and therapeutics.

Yunbao Pan1,2, Guohong Liu3,4, Fuling Zhou5, Bojin Su6, Yirong Li7.   

Abstract

Cancer initiation and proliferation is regulated by both epigenetic and genetic events with epigenetic modifications being increasingly identified as important targets for cancer research. DNA methylation catalyzed by DNA methyltransferases (DNMTs) is one of the essential epigenetic mechanisms that control cell proliferation, apoptosis, differentiation, cell cycle, and transformation in eukaryotes. Recent progress in epigenetics revealed a deeper understanding of the mechanisms of tumorigenesis and provided biomarkers for early detection, diagnosis, and prognosis in cancer patients. Although DNA methylation biomarker possesses potential contributing to precision medicine, there are still limitations to be overcome before it reaches clinical setting. Hence, the current status of DNA methylation biomarkers was reviewed and the future use in clinic was also predicted.

Entities:  

Keywords:  Biomarker; Cancer; DNA methylation; DNMT inhibitor; Epigenetics

Mesh：

Substances：

Year:  2017        PMID： 28752221     DOI： 10.1007/s10238-017-0467-0

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN： 1591-8890            Impact factor:   3.984


  160 in total

1.  Assessment of Promoter Methylation Identifies PTCH as a Putative Tumor-suppressor Gene in Human CLL.

Authors:  Ingo G H Schmidt-Wolf; Christoph Plass; John C Byrd; Kathrin Frevel; Torsten Pietsch; Andreas Waha
Journal:  Anticancer Res       Date:  2016-09       Impact factor: 2.480

Review 2.  Epigenetic DNA methylation in radiation biology: on the field or on the sidelines?

Authors:  Steven P Zielske
Journal:  J Cell Biochem       Date:  2015-02       Impact factor: 4.429

Review 3.  APC gene hypermethylation and prostate cancer: a systematic review and meta-analysis.

Authors:  Yang Chen; Jie Li; Xiaoxiang Yu; Shuai Li; Xuerong Zhang; Zengnan Mo; Yanling Hu
Journal:  Eur J Hum Genet       Date:  2013-01-09       Impact factor: 4.246

Review 4.  From discovery to the clinic: the novel DNA methylation biomarker (m)SEPT9 for the detection of colorectal cancer in blood.

Authors:  Shannon R Payne
Journal:  Epigenomics       Date:  2010-08       Impact factor: 4.778

5.  Genome-wide identification and validation of a novel methylation biomarker, SDC2, for blood-based detection of colorectal cancer.

Authors:  TaeJeong Oh; Nayoung Kim; Youngho Moon; Myung Soon Kim; Benjamin D Hoehn; Chan Hee Park; Tae Soo Kim; Nam Kyu Kim; Hyun Cheol Chung; Sungwhan An
Journal:  J Mol Diagn       Date:  2013-06-07       Impact factor: 5.568

6.  DNMT3A mutations in acute myeloid leukemia.

Authors:  Timothy J Ley; Li Ding; Matthew J Walter; Michael D McLellan; Tamara Lamprecht; David E Larson; Cyriac Kandoth; Jacqueline E Payton; Jack Baty; John Welch; Christopher C Harris; Cheryl F Lichti; R Reid Townsend; Robert S Fulton; David J Dooling; Daniel C Koboldt; Heather Schmidt; Qunyuan Zhang; John R Osborne; Ling Lin; Michelle O'Laughlin; Joshua F McMichael; Kim D Delehaunty; Sean D McGrath; Lucinda A Fulton; Vincent J Magrini; Tammi L Vickery; Jasreet Hundal; Lisa L Cook; Joshua J Conyers; Gary W Swift; Jerry P Reed; Patricia A Alldredge; Todd Wylie; Jason Walker; Joelle Kalicki; Mark A Watson; Sharon Heath; William D Shannon; Nobish Varghese; Rakesh Nagarajan; Peter Westervelt; Michael H Tomasson; Daniel C Link; Timothy A Graubert; John F DiPersio; Elaine R Mardis; Richard K Wilson
Journal:  N Engl J Med       Date:  2010-11-10       Impact factor: 91.245

7.  DNA methyltransferase and demethylase in human prostate cancer.

Authors:  Samir K Patra; Aditi Patra; Hong Zhao; Rajvir Dahiya
Journal:  Mol Carcinog       Date:  2002-03       Impact factor: 4.784

8.  Quantitative detection of methylated ESR1 and 14-3-3-sigma gene promoters in serum as candidate biomarkers for diagnosis of breast cancer and evaluation of treatment efficacy.

Authors:  Joaquina Martínez-Galán; Blanca Torres; Rosario Del Moral; José Antonio Muñoz-Gámez; David Martín-Oliva; Mercedes Villalobos; María Isabel Núñez; Juan de Dios Luna; Francisco Javier Oliver; José Mariano Ruiz de Almodóvar
Journal:  Cancer Biol Ther       Date:  2008-03-20       Impact factor: 4.742

9.  Multitarget stool DNA testing for colorectal-cancer screening.

Authors:  Thomas F Imperiale; David F Ransohoff; Steven H Itzkowitz; Theodore R Levin; Philip Lavin; Graham P Lidgard; David A Ahlquist; Barry M Berger
Journal:  N Engl J Med       Date:  2014-03-19       Impact factor: 91.245

10.  Aberrant GSTP1 promoter methylation is associated with increased risk and advanced stage of breast cancer: a meta-analysis of 19 case-control studies.

Authors:  Cheng Fang; Xue-Mei Wei; Xian-Tao Zeng; Fu-Bing Wang; Hong Weng; Xinghua Long
Journal:  BMC Cancer       Date:  2015-11-19       Impact factor: 4.430
View more
  108 in total

1.  Impact of estrogen receptor α on the tamoxifen response and prognosis in luminal-A-like and luminal-B-like breast cancer.

Authors:  Nataliya Babyshkina; Sergey Vtorushin; Tatyana Dronova; Stanislav Patalyak; Elena Slonimskaya; Julia Kzhyshkowska; Nadejda Cherdyntseva; Evgeny Choynzonov
Journal:  Clin Exp Med       Date:  2019-09-27       Impact factor: 3.984

2.  Promoter aberrant methylation status of ADRA1A is associated with hepatocellular carcinoma.

Authors:  Guoqiao Chen; Xiaoxiao Fan; Yirun Li; Lifeng He; Shanjuan Wang; Yili Dai; Cui Bin; Daizhan Zhou; Hui Lin
Journal:  Epigenetics       Date:  2020-01-14       Impact factor: 4.528

Review 3.  Epigenetic polypharmacology: A new frontier for epi-drug discovery.

Authors:  Daniela Tomaselli; Alessia Lucidi; Dante Rotili; Antonello Mai
Journal:  Med Res Rev       Date:  2019-06-20       Impact factor: 12.944

Review 4.  Patterns of DNA methylation as an indicator of biological aging: State of the science and future directions in precision health promotion.

Authors:  Shannon L Gillespie; Lynda R Hardy; Cindy M Anderson
Journal:  Nurs Outlook       Date:  2019-05-17       Impact factor: 3.250

Review 5.  SIX3 function in cancer: progression and comprehensive analysis.

Authors:  Tian-Liang Ma; Peng Zhu; Jing-Xian Chen; Yi-He Hu; Jie Xie
Journal:  Cancer Gene Ther       Date:  2022-06-28       Impact factor: 5.987

6.  Frequent promoter methylation of HOXD10 in endometrial carcinoma and its pathological significance.

Authors:  Fan Yang; Dongchen Liu; Yupeng Deng; Jun Wang; Shuyu Mei; Shuang Ge; Hailing Li; Cuijuan Zhang; Tingguo Zhang
Journal:  Oncol Lett       Date:  2020-03-19       Impact factor: 2.967

7.  Methylation of the HOXA10 Promoter Directs miR-196b-5p-Dependent Cell Proliferation and Invasion of Gastric Cancer Cells.

Authors:  Linlin Shao; Zheng Chen; Wael El-Rifai; Dunfa Peng; Mohammed Soutto; Shoumin Zhu; Andreia Bates; Shutian Zhang
Journal:  Mol Cancer Res       Date:  2018-02-16       Impact factor: 5.852

Review 8.  Ketotherapy as an epigenetic modifier in cancer.

Authors:  Borja Bandera-Merchan; Hatim Boughanem; Ana B Crujeiras; Manuel Macias-Gonzalez; Francisco J Tinahones
Journal:  Rev Endocr Metab Disord       Date:  2020-12       Impact factor: 6.514

Review 9.  The regulation mechanisms and the Lamarckian inheritance property of DNA methylation in animals.

Authors:  Yulong Li; Yujing Xu; Tongxu Liu; Hengyi Chang; Xiaojun Yang
Journal:  Mamm Genome       Date:  2021-04-15       Impact factor: 2.957

10.  Integrated analysis of methylation-driven genes and pretreatment prognostic factors in patients with hepatocellular carcinoma.

Authors:  Dongsheng He; Shengyin Liao; Lifang Cai; Weiming Huang; Xuehua Xie; Mengxing You
Journal:  BMC Cancer       Date:  2021-05-25       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.